Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349721 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
A Phase 2 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT05349721 is a Phase 2 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 336 participants.
The verdict
NCT05349721, a Phase 2 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
Interventions
- DRUG Placebo
- DRUG PTC857
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05349721
The ClinicalTrials.gov registry entry for NCT05349721 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05349721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05349721 about?
NCT05349721 is a clinical study titled "Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS". This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
What is the current status of trial NCT05349721?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2022-05-15. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT05349721?
The interventions under investigation include: Placebo (DRUG), PTC857 (DRUG).
Who is sponsoring clinical trial NCT05349721?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.